Gyre Therapeutics, Inc. Earnings Per Share (Basic)
Gyre Therapeutics, Inc. (GYRE) reported Earnings Per Share (Basic) of -$0.12 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-07
- Gyre Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.12.
- Gyre Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.10, a 433.33% decline year-over-year.
- Gyre Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.02.
- Gyre Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-09-30 was $0.04, a 300.00% increase year-over-year.
- Gyre Therapeutics, Inc. earnings per share, basic for fiscal 2025 was $0.06, a 57.14% decline from fiscal 2024.
- Gyre Therapeutics, Inc. earnings per share, basic for fiscal 2024 was $0.14.
- Gyre Therapeutics, Inc. earnings per share, basic for fiscal 2023 was -$1.41, a 3625.00% decline from fiscal 2022.
- Gyre Therapeutics, Inc. earnings per share, basic for fiscal 2022 was $0.04.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.12 10-Q · filed 2026-08-07 | -$0.26 10-Q · filed 2026-08-07 | -$0.23 derived: net income ÷ weighted average shares · filed 2026-08-07 | -$0.20 derived: net income ÷ weighted average shares · filed 2026-08-07 | ||||
| 2026-03-31 | -$0.10 10-Q · filed 2026-05-08 | -$0.11 derived: net income ÷ weighted average shares · filed 2026-05-08 | -$0.07 derived: net income ÷ weighted average shares · filed 2026-05-08 | -$0.10 derived: net income ÷ weighted average shares · filed 2026-08-07 | ||||
| 2025-12-31 | -$0.02 derived: net income ÷ weighted average shares · filed 2026-03-13 | $0.02 derived: net income ÷ weighted average shares · filed 2026-03-13 | -$0.00 derived: net income ÷ weighted average shares · filed 2026-08-07 | $0.06 10-K · filed 2026-03-13 | ||||
| 2025-09-30 | $0.04 10-Q · filed 2025-11-07 | $0.02 derived: net income ÷ weighted average shares · filed 2026-08-07 | $0.08 10-Q · filed 2025-11-07 | $0.05 derived: net income ÷ weighted average shares · filed 2026-08-07 | ||||
| 2025-06-30 | -$0.02 10-Q · filed 2026-08-07 | $0.00 10-Q · filed 2025-08-11 | $0.00 10-Q · filed 2026-08-07 | $0.04 10-Q · filed 2025-08-11 | $0.01 derived: net income ÷ weighted average shares · filed 2026-08-07 | $0.02 derived: net income ÷ weighted average shares · filed 2026-08-07 | ||
| 2025-03-31 | $0.03 10-Q · filed 2026-05-08 | $0.03 derived: net income ÷ weighted average shares · filed 2026-05-08 | $0.04 derived: net income ÷ weighted average shares · filed 2026-05-08 | $0.08 derived: net income ÷ weighted average shares · filed 2026-05-08 | ||||
| 2024-12-31 | -$0.00 derived: net income ÷ weighted average shares · filed 2026-03-13 | $0.01 derived: net income ÷ weighted average shares · filed 2026-03-13 | $0.05 derived: net income ÷ weighted average shares · filed 2026-03-13 | $0.14 10-K · filed 2026-03-13 | ||||
| 2024-09-30 | $0.01 10-Q · filed 2025-11-07 | $0.05 derived: net income ÷ weighted average shares · filed 2025-11-07 | $0.14 10-Q · filed 2025-11-07 | -$1.09 derived: net income ÷ weighted average shares · filed 2025-11-07 | ||||
| 2024-06-30 | $0.04 10-Q · filed 2025-08-11 | $0.13 10-Q · filed 2025-08-11 | -$1.12 derived: net income ÷ weighted average shares · filed 2025-08-11 | -$1.13 derived: net income ÷ weighted average shares · filed 2025-08-11 | ||||
| 2024-03-31 | $0.09 10-Q · filed 2025-05-09 | -$1.20 derived: net income ÷ weighted average shares · filed 2025-05-09 | -$1.22 derived: net income ÷ weighted average shares · filed 2025-05-09 | -$1.24 derived: net income ÷ weighted average shares · filed 2025-05-09 | ||||
| 2023-12-31 | -$1.39 derived: net income ÷ weighted average shares · filed 2025-03-17 | -$1.43 derived: net income ÷ weighted average shares · filed 2025-03-17 | -$1.43 derived: net income ÷ weighted average shares · filed 2025-03-17 | -$1.41 10-K · filed 2025-03-17 | ||||
| 2023-09-30 | $0.06 10-Q · filed 2024-11-13 | -$0.04 10-Q · filed 2023-10-26 | $0.09 derived: net income ÷ weighted average shares · filed 2024-11-13 | $0.13 10-Q · filed 2024-11-13 | -$0.10 10-Q · filed 2023-10-26 | -$0.25 derived: net income ÷ weighted average shares · filed 2024-11-13 | ||
| 2023-06-30 | $0.03 10-Q · filed 2024-08-13 | -$0.07 10-Q · filed 2023-08-14 | $0.06 10-Q · filed 2024-08-13 | -$0.06 10-Q · filed 2023-08-14 | -$0.27 derived: net income ÷ weighted average shares · filed 2024-08-13 | -$0.39 derived: net income ÷ weighted average shares · filed 2024-08-13 | ||
| 2023-03-31 | $0.04 10-Q · filed 2024-05-13 | $0.01 10-Q · filed 2023-05-15 | -$0.25 derived: net income ÷ weighted average shares · filed 2024-05-13 | -$0.38 derived: net income ÷ weighted average shares · filed 2024-05-13 | $0.27 derived: net income ÷ weighted average shares · filed 2024-05-13 | |||
| 2022-12-31 | -$0.19 derived: net income ÷ weighted average shares · filed 2024-03-27 | -$0.36 derived: net income ÷ weighted average shares · filed 2024-03-27 | $0.23 derived: net income ÷ weighted average shares · filed 2024-03-27 | $0.04 10-K · filed 2024-03-27 | -$0.26 10-K · filed 2023-03-30 | |||
| 2022-09-30 | -$0.16 10-Q · filed 2023-10-26 | $1.48 derived: net income ÷ weighted average shares · filed 2023-10-26 | $1.02 10-Q · filed 2023-10-26 | |||||
| 2022-06-30 | $1.64 10-Q · filed 2023-08-14 | $1.18 10-Q · filed 2023-08-14 | ||||||
| 2022-03-31 | -$0.46 10-Q · filed 2023-05-15 | |||||||
| 2021-12-31 | -$2.87 10-K · filed 2023-03-30 | |||||||
| 2021-09-30 | -$0.80 10-Q · filed 2022-11-14 | -$1.44 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$2.23 10-Q · filed 2022-11-14 | |||||
| 2021-06-30 | -$0.64 10-Q · filed 2022-08-15 | -$1.42 10-Q · filed 2022-08-15 | ||||||
| 2014-12-31 | -$0.14 10-K · filed 2015-03-16 | |||||||
| 2014-09-30 | -$0.14 10-K · filed 2015-03-16 | |||||||
| 2014-06-30 | -$0.24 10-K · filed 2015-03-16 | |||||||
| 2014-03-31 | -$0.44 10-K · filed 2015-03-16 | |||||||
| 2013-12-31 | -$0.40 10-K · filed 2015-03-16 | |||||||
| 2013-09-30 | -$0.38 10-K · filed 2015-03-16 | -$0.99 10-Q · filed 2013-11-06 | ||||||
| 2013-06-30 | -$0.37 10-K · filed 2015-03-16 | -$0.61 10-Q · filed 2013-08-07 | ||||||
| 2013-03-31 | -$0.24 10-K · filed 2015-03-16 | |||||||
| 2012-12-31 | -$0.47 10-K · filed 2014-03-14 | -$0.21 10-K · filed 2013-03-15 | ||||||
| 2012-09-30 | -$0.24 10-K · filed 2014-03-14 | $0.27 10-Q · filed 2013-11-06 | ||||||
| 2012-06-30 | $0.43 10-K · filed 2014-03-14 | $0.50 10-Q · filed 2013-08-07 | ||||||
| 2012-03-31 | $0.07 10-K · filed 2014-03-14 | |||||||
| 2011-12-31 | -$0.29 10-K · filed 2013-03-15 | -$0.27 10-K · filed 2013-03-15 | ||||||
| 2011-09-30 | -$0.27 10-K · filed 2013-03-15 | $0.04 10-Q · filed 2012-11-08 | ||||||
| 2011-06-30 | -$0.07 10-K · filed 2013-03-15 | $0.35 10-Q · filed 2012-08-09 | ||||||
| 2011-03-31 | $0.43 10-K · filed 2013-03-15 | |||||||
| 2010-12-31 | $0.38 10-K · filed 2013-03-15 | |||||||
| 2010-09-30 | $0.09 10-Q · filed 2011-11-03 | $0.46 10-Q · filed 2011-11-03 | ||||||
| 2010-06-30 | $0.13 10-Q · filed 2011-08-09 | $0.37 10-Q · filed 2011-08-09 | ||||||
| 2009-12-31 | -$1.54 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |